ATHENA-HF Trial

The Aldosterone Targeted Neurohormonal Combined with Natriuresis Therapy – HF trial studied the effect of high-dose spironolactone on outcomes including N-terminal pro-B type natriuretic peptide levels in patients with acute HF.

Design: Randomized, double blind, placebo-controlled

Patients: 360

Centers: 22

Country: United States

Results: At 96 hours or discharge, change in log NT-pro BNP was –0.49 (95% CI, –0.98 to –0.14) in the usual care group and –0.55 (95% CI, –0.92 to –0.18) in the high-dose spironolactone group (P = .57). Absolute changes in NT-proBNP at 96 hours or discharge were –1,072 pg/mL (95% CI, –3,182 to –231) in the usual care group and –1796 (95% CI, –3883 to –571) in the high-dose spironolactone group (P = .76).

Original Publications:
Butler J, et al. JACC Heart Fail. 2016:doi;10.1016/j.jchf.2016.06.003.

Healio/Cardiology News Coverage:
ATHENA-HF: High-dose spironolactone does not benefit patients with acute HF